Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00139867
Status:
COMPLETED
Last Update Posted:
2014-10-20
First Post:
2005-08-29
Brief Title:
A Multicenter Open-label Trial to Assess Subject Preference of PARCOPA CarbidopaLevodopa Orally Disintegrating Tablets Compared to Conventional CarbidopaLevodopa Tablets in Subjects With Stable Parkinsons Disease
Sponsor:
UCB Pharma
Organization:
UCB Pharma
Study Overview
Official Title:
A Multicenter Open-label Trial to Assess Subject Preference of PARCOPA CarbidopaLevodopa Orally Disintegrating Tablets Compared to Conventional CarbidopaLevodopa Tablets in Subjects With Stable Parkinsons Disease
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this trial was to assess subject preference for PARCOPA carbidopalevodopa Orally Disintegrating Tablets ODT compared with conventional carbidopalevodopa tablets in subjects with stable Parkinsons disease
Detailed Description:
See approved Package Insert for Adverse Event information
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None